Journal ArticleDOI
Enhanced pressor sensitivity to oral tyramine challenge following high dose selegiline treatment.
Reads0
Chats0
TLDR
It is suggested that patients treated with selegiline 30 mg/day or more should be placed on a tyramine-free diet.Abstract:
Blood pressure and heart rate responses to oral tyramine have been measured in healthy volunteers before and after administration of the selective monoamine oxidase B inhibitor selegiline at high dosage (30 mg/day). Treatment brought about a 2 to 4-fold increase in tyramine sensitivity and a concomitant small but significant reduction in plasma 4-hydroxy-3-methoxyphenylglycol concentration, pointing to the emergence of some degree of monoamine oxidase A inhibition. It is suggested that patients treated with selegiline 30 mg/day or more should be placed on a tyramine-free diet.read more
Citations
More filters
Journal ArticleDOI
A review of the pharmacology of selegiline.
E. H. Heinonen,R. Lammintausta +1 more
TL;DR: Besides the inhibition of MAO‐B, selegiline also inhibits the uptake of dopamine and noradrenaline into presynaptic nerve and increases the turnover of dopamine, which significantly potentiates the pharmacological effects of levodopa.
Journal ArticleDOI
Pharmacokinetics and metabolism of selegiline
Heinonen E H,Myllylä,Kyösti A. Sotaniemi,Lammintausta R,Salonen J S,Anttila M,Savijärvi M,Kotila M,Rinne U K +8 more
TL;DR: The steady state concentrations of the metabolites in the serum and cerebrospinal fluid of patients with Parkinson's or Alzheimer's diseases who were on continuous selegiline therapy were similar, and were not affected by the addition of levodopa.
Journal ArticleDOI
Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.
TL;DR: There is strong evidence to suggest that selegiline should be considered both in patients newly diagnosed with Parkinson's disease in an attempt to delay symptom progression, and in those experiencing dose-dependent fluctuations in response to levodopa.
Journal ArticleDOI
Selegiline in the treatment of Parkinson's disease.
E H Heinonen,U. K. Rinne +1 more
TL;DR: In animal models selegiline has been shown to prevent parkinsonism caused by MPTP and also to increase the life span of rats, and whether seLegiline slows down the progression of Parkinson's disease needs further examination.
References
More filters
Journal ArticleDOI
Some observations upon a new inhibitor of monoamine oxidase in brain tissue.
TL;DR: The hypothesis that in the enzyme prepared, the MAO is a binary system of enzymes each of which has a detectably different sensitivity to this particular inhibitor, is put forward and evidence after dialysis supports this hypothesis.
Journal ArticleDOI
Deprenyl in parkinson's disease
Andrew J. Lees,L.J. Kohout,K.M. Shaw,G. M. Stern,J. D. Elsworth,M. Sandler,Moussa B.H. Youdim +6 more
TL;DR: In this article, (-)-deprenyl, a fast-acting selective monoamine-oxidase-B inhibitor without a "cheese effect", was given to 41 patients with idiopathic Parkinson's disease who were receiving maximum tolerated doses of levodopa either alone or combined with carbidopa ("Sinemet").
Journal ArticleDOI
Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ‘cheese effect’
J. D. Elsworth,Vivette Glover,Gavin P. Reynolds,M. Sandler,Andrew J. Lees,P. Phuapradit,K.M. Shaw,G. M. Stern,Parveen Kumar +8 more
TL;DR: Oral phenylethylamine challenge with amounts greater than those known to be present in a normal diet similarly gave rise to no adverse reaction in (-)-deprenyl-treated subjects; the reasons for this remain to be determined.
Journal ArticleDOI
Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation.
TL;DR: Clorgyline had generally greater antidepressant and antianxiety effects than did pargYline, although pargyline had some activating effects and also tended to produce more side effects, suggesting MAO type A inhibition may be more important than MAOtype B inhibition for antidepressant efficacy.